Recent News

Channel Medsystems® Secures $14.1mm Financing for Office-Based Treatment of Heavy Menstrual Bleeding

Emeryville, CA - August 23, 2017 -- Channel Medsystems, developer of an innovative, physician office-based therapy for heavy menstrual bleeding, announced today that it has secured a $14.1mm Series C-1 financing. The insider-led round included participation by Third Point Ventures, InCube Ventures, Aperture Venture Partners, Scientific Health Development, Longwood Fund, and Boston Scientific. For full story click here...

Complexa Raises $62 Million in Series C Financing to Test CXA-10 in Two Orphan Disease Proof-of-Concept Trials

Radnor, PA - July 26, 2017 -- Complexa Inc., a clinical stage biopharmaceutical company, today announced the completion of a $62 million Series C funding round led by New Enterprise Associates (NEA) and Pfizer Venture Investments, LLC. Participation in this round also included Edmond de Rothschild Investment Partners, HBM Healthcare Investments and existing investors including JAFCO Co., Ltd. (JAFCO), which led the Company's Series B financing in 2014. For full story click here...

Podimetrics Publishes Landmark Study Demonstrating 97% Sensitivity in Predicting Emergence of Diabetic Foot Ulcers Five Weeks Prior to Clinical Presentation

Somerville, MA - June 29, 2017 --Podimetrics, Inc., a medtech and services company focused on the early detection and prevention of diabetic foot ulcers (DFU), announced today the publication of a landmark study in the July issue of Diabetes Care. Results demonstrate that the Podimetrics SmartMat™ detected as many as 97% of developing nontraumatic plantar foot ulcers on average five weeks before they presented clinically. Importantly, 86% of patients used the mat at least three times per week and 88% of respondents reported it being easy-to-use, suggesting that patients readily accept this practical, new monitoring technology. For full story click here...

Channel Medsystems® Earns CE Mark Approval for the Cerene® Cryotherapy Device

Emeryville, CA - June 26, 2017 -- Channel Medsystems, the developer of an innovative, physician office-based therapy for heavy menstrual bleeding, announced today that it has earned CE Mark approval, allowing the Company to initiate marketing efforts and commercialization of its Cerene Cryotherapy Device (Cerene device) in Europe. The Cerene device is intended for endometrial cryoablation in premenopausal women with heavy menstrual bleeding due to benign causes in whom childbearing is complete. For full story click here...

Potrero Study Demonstrates New Standard of Care for Accurately Measuring Intra-Abdominal Pressure in Critical Care Patients

Northfield, IL - June13, 2017 --The prevalence of intra-abdominal hypertension (IAH) in the critically ill is reported to be as high as 50 percent and is a significant cause of abdominal compartment syndrome (ACS), morbidity and mortality. Diagnosis requires an accurate, reliable and consistent standardized methodology for measuring intra-abdominal pressure (IAP). The accuracy of the intra-vesical pressure (IVP) method, the current standard-of-care measurement method, is hindered by “self-assembly” set-up, which is performed manually and introduces non-standardized construction, clinical technique and quality control challenges. It is often time-consuming, leads to errors and can put patients at risk for infection. For full story click here...

Sight Sciences Announces Health Canada Approval of the VISCO™360 Viscosurgical System for Standalone Microinvasive Glaucoma Surgery (MIGS)

Menlo Park, CA - April 13, 2017 -- Sight Sciences, Inc., a venture-backed, commercial stage ophthalmic medical device company announced today that it has received Health Canada approval for the VISCO™360 Viscosurgical System. The VISCO360 System is indicated in Canada for the microcatheterization and transluminal viscodilation of Schlemm's canal to reduce intraocular pressure (IOP) in adult patients with open-angle glaucoma.* Performed as a standalone MIGS procedure, the first commercial VISCO360 cases in Canada were successfully carried out by Dr. Ike Ahmed, world-renowned ophthalmologist recognized for his extensive experience in the diagnosis and surgical treatment of glaucoma. For full story click here...

Channel Medsystems Completes Treatments in Largest Single-Arm Pivotal Study of Endometrial Ablation; Demonstrates Feasibility of Comfortable, Office-Based Procedure

Emeryville, CA - March 20, 2017 -- Channel Medsystems, the developer of an innovative, physician office-based therapy for heavy menstrual bleeding, announced the successful completion of the treatment phase in its CLARITY Pivotal Study. The goal of the CLARITY study is to evaluate the safety and effectiveness of the Cerene® Cryotherapy Device (Cerene device) in 242 women with heavy menstrual bleeding who are finished with childbearing. For full story click here...

Medline Joins Forces with Potrero Medical to Transform Critical Care Monitoring

Northfield, IL - January 23, 2017 -- Medline Industries, Inc., a leading global healthcare manufacturer and distributor, and Potrero Medical, Inc., a privately held medical device company and the developer of the Accuryn™ critical care monitoring system, today announced a joint partnership to expand commercialization and continue clinical investigations to further support the benefits of the Accuryn critical care monitoring system. For full story click here...

Sight Sciences Announces Health Canada Approval of the TRAB™360 Trabeculotomy System

Menlo Park, CA - Dec 23, 2016 -- Sight Sciences, Inc., a venture-backed, commercial-stage ophthalmic medical device company announced today that it has received Health Canada approval for the TRAB™360 Trabeculotomy System. The TRAB™360 is indicated in Canada for the microcatheterization of Schlemm's canal and cutting of trabecular meshwork to lower intraocular pressure (IOP) in patients with primary open angle glaucoma. From a single clear corneal incision, the TRAB™360 surgeon can complete a 360-degree trabeculotomy. For full story click here...

Channel Medsystems Secures IDE Approval and Treats First Women in the CLARITY Pivotal Study

Emeryville, CA - Nov. 14, 2016 -- Channel Medsystems, the developer of an innovative, physician office-based therapy for heavy menstrual bleeding, announced the treatment of the first subjects in the US phase of its CLARITY Pivotal Study. CLARITY is a multicenter study to evaluate the safety and effectiveness of the Cerene™ Cryotherapy Device for endometrial ablation in women with heavy menstrual bleeding who are finished with childbearing. For full story click here...

Azevan Pharmaceuticals Reports Positive Phase 2 Exploratory Clinical Study Results with SRX246 in Intermittent Explosive Disorder

Bethlehem, PA - September 14, 2016 -- Azevan Pharmaceuticals, Inc. (www.azevan.com) announced results from the phase 2 exploratory clinical study of the Company's lead compound, SRX246, in adults with Intermittent Explosive Disorder. The study was a multi-center, randomized, double blind, placebo controlled trial in 97 adult male and female subjects. It included a two-week placebo lead-in phase and then randomization to SRX246 or placebo for 8 weeks. For full story click here...

Sight Sciences Announces CE Mark Approval for and Successful Commercial Experiences with the VISCO™360 Viscosurgical System for the Surgical Treatment of Glaucoma

Menlo Park, CA - September 9, 2016 -- Sight Sciences, Inc., a venture-backed, commercial stage ophthalmic medical device company announced today that the initial European commercial cases with the CE mark approved VISCO™360 Viscosurgical System will be presented Monday morning, September 12th during the European Society of Cataract and Refractive Surgeons (ESCRS) meeting in Copenhagen, Denmark. For full story click here...

Sight Sciences Receives Full Investigational Device Exemption (IDE) Approval from the US FDA to Initiate the VISCO™360 versus SLT Glaucoma Trial

Menlo Park, CA - July 26, 2016 -- Sight Sciences, Inc., a venture-backed, commercial-stage ophthalmic medical device company announced today that it has received full IDE approval from the FDA to initiate the world's first clinical trial comparing ab interno canaloplasty with Selective Laser Trabeculoplasty (SLT). The VISCO™360 versus SLT Glaucoma Trial is a multi-center, prospective, randomized, controlled clinical evaluation that will study the safety and effectiveness of the Sight Sciences VISCO™360 Viscosurgical System in canaloplasty versus SLT in the reduction of intraocular pressure (IOP) in primary open angle glaucoma. For full story click here...

Potrero Medical, Inc. Receives FDA Clearance for the Accuryn™ Monitoring System

San Francisco, CA - April 26, 2016 -- Potrero Medical, Inc. announced today that it received 510 (k) clearance through the Food and Drug Administration (FDA) for the company's Accuryn™ Monitoring System, which transforms the traditional urinary catheter into a next-generation diagnostic tool for patients requiring tight fluid management, including patients at risk of sepsis and acute kidney injury. For full story click here...

Potrero Medical Commences NIH-backed PRESCIENT Study of Accuryn™ For Early Detection of Critical Illness

San Francisco, CA - February 2, 2016 -- Potrero Medical, Inc. today announced the start of the PRESCIENT study, an NIH-sponsored, multi-center observational study using the Accuryn™ Monitoring System to detect the physiological signatures of critical illnesses, including sepsis. For full story click here...

Allergan Acquires Medical Dermatology and Aesthetic Medicine Company Anterios to Expand Neurotoxin Pipeline

Dublin, Ireland and New York, NY - January 7, 2016 -- Allergan plc (NYSE: AGN), a leading global pharmaceutical company, today announced that it has acquired Anterios, Inc., a clinical stage biopharmaceutical company developing a next generation delivery system and botulinum toxin-based prescription products. Under the terms of the agreement, Allergan acquired Anterios for an upfront payment of $90 million and potential development and commercialization milestone payments related to NDS, Anterios' proprietary platform delivery technology that enables local, targeted delivery of neurotoxins through the skin without the need for injections. For full story click here...